Therapeutic strategies targeting TAMs in PCa include macrophage depletion by blocking CSF1R signaling, inhibition of the recruitment of macrophages into the tumor microenvironment via blocking CCL2/CCR2 signaling and macrophage reprogramming towards tumoricidal classically activated phenotype via CD40 agonists or inhibition of the “do not eat me” CD47-SIRPα signaling axis to promote tumor cell phagocytosis [15]. The gene discussed is CCR2; the disease is neoplasm.